Modified bone marrow mesenchymal stem cells derived exosomes loaded with MiRNA ameliorates non-small cell lung cancer

Area of Science:

• Biomedical Engineering
• Oncology
• Cell Biology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
• Exosomes derived from bone marrow mesenchymal stem cells (BMSC-Exos) are emerging as potential drug delivery vehicles.
• Targeted delivery of therapeutic agents to NSCLC cells is crucial for improving treatment efficacy and reducing side effects.

Purpose of the Study:

• To investigate the function of LXY30 peptide-modified BMSC-Exos (LXY30-Exos) in NSCLC treatment.
• To evaluate the therapeutic potential of LXY30-Exos loaded with miR-30c, miR-181b, or miR-613.
• To assess the in vitro and in vivo efficacy and safety of these engineered exosomes.

Main Methods:

• LXY30-Exos were engineered by modifying BMSC-Exos with LXY30 peptide, a ligand targeting α3β1 integrin.
• Transmission electron microscopy and particle tracking analysis were used for LXY30-Exos identification and characterization.
• In vitro assays (proliferation, migration, apoptosis) and in vivo tumor models were employed to assess therapeutic effects. Molecular technologies verified exosome internalization and tumor targeting.

Main Results:

• LXY30-Exos were successfully identified, internalized by NSCLC cells in vitro, and specifically targeted NSCLC tumors in vivo.
• LXY30-Exos loaded with miR-30c, miR-181b, or miR-613 significantly weakened NSCLC cell proliferation and migration, induced apoptosis, and inhibited tumor progression in vivo.
• In vivo safety evaluations confirmed the tolerability of the engineered exosomes.

Conclusions:

• LXY30 peptide modification enhances the targeting ability of BMSC-Exos for NSCLC.
• Encapsulation of miR-30c, miR-181b, or miR-613 within LXY30-Exos demonstrates significant anti-NSCLC activity.
• LXY30-Exos loaded with these microRNAs represent a promising targeted therapy for NSCLC with a favorable safety profile.